GlassScriptPhysician profile
Sarah Marmol
NPI 1700380193
$67,793.05
in general payments reported to CMS, 2019-2025
15 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.44 · 2022: $44K · 2023: $15K · 2024: $7,766 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $21K · Food and Beverage: $1,815 · Travel and Lodging: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $21,136.36 |
| Food and Beverage | $1,815.02 |
| Travel and Lodging | $339.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27,287.33 | 2022-2023 | Infinity |
| Medtronic, INC. | $21,824.49 | 2022-2023 | Percept PC Brainsense, Activa PC |
| Boston Scientific Corporation | $15,255.02 | 2022-2025 | Vercise, General - Dbs |
| Biogen, INC. | $1,862.36 | 2022 | |
| Amneal Pharmaceuticals LLC | $446.01 | 2023-2025 | Rytary, Crexont |
| Abbvie INC. | $421.86 | 2024-2025 | |
| Ucb, INC. | $263.92 | 2021-2025 | |
| Neurelis, INC. | $124.99 | 2024 | Valtoco |
| Revance Therapeutics, INC. | $88.16 | 2025 | Daxxify |
| Jazz Pharmaceuticals INC. | $67.19 | 2025 | |
| Acadia Pharmaceuticals INC | $37.60 | 2025 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $30.82 | 2023 | Fycompa |
| Mdd US Operations, LLC | $29.54 | 2025 | Apokyn |
| Lundbeck LLC | $27.30 | 2025 | Vyepti |
| Novo Nordisk INC | $26.46 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Marmol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.